Side Effects of Immune Checkpoint Blockade The wide range of immune-related adverse
effects associated with immune checkpoint blockade can complicate this effective therapy …

Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in
humans, with an estimated incidence of 1 million cases each year in the United States …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Purpose To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events in patients treated with …

Immunotherapy with monoclonal antibodies (MoAbs) targeting cytotoxic T lymphocyte-
associated antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its ligand …

Summary Glucagon-like peptide-1 receptor (GLP-1R) is a key regulator of glucose
metabolism known to be expressed by pancreatic β cells. We herein investigated the role of …

Abstract Background Checkpoint inhibitors (CPIs) have revolutionized the treatment of
cancer, but their use remains limited by off-target inflammatory and immune-related adverse …

Characterizing the tumor immune microenvironment enables the identification of new
prognostic and predictive biomarkers, the development of novel therapeutic targets and …

Immune checkpoint inhibitors, including those targeting the programmed cell death
1/programmed cell death ligand 1 and cytotoxic T lymphocyte antigen 4 pathways, are …

Background: Cancer immunotherapy, such as anti-cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) and anti-programmed death 1 (PD-1), has revolutionized the treatment of …